A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recent studies have focused on the role of inflammatory cascades as one of the possible etiologic factors of bipolar disorder. We hypothesize that celecoxib, through its anti-inflammatory properties, may have a therapeutic role in acute bipolar mania. PATIENTS AND METHODS: Forty-two adolescent inpatients with the diagnosis of acute bipolar mania participated in a parallel, randomized, double-blind controlled trial, and 40 patients underwent an 8-week treatment with either celecoxib (100 mg twice daily) or placebo as an adjunctive treatment to lithium and risperidone. Patients were evaluated using Young Mania Rating Scale (YMRS) at baseline and weeks 2, 4, and 8. The primary outcome measure was to assess the efficacy of celecoxib compared with placebo in improving mania symptoms. RESULT: General linear model repeated measures showed significant effect for time × treatment interaction on YMRS scores [F (2.54, 96.56) = 3.21, p = 0.03]. Significantly greater improvement was observed in YMRS scores in the celecoxib group compared with the placebo group from baseline YMRS score at week 8 (p = 0.04). Although a 35% greater response to treatment (considering a Clinical Global Impressions-Improvement score of ≤2, very much/much improved) was observed in the celecoxib group compared with the placebo group, the difference did not reach the statistical significance level (p = 0.09). No serious adverse event was reported. CONCLUSIONS: Celecoxib may be an effective adjuvant therapy in treatment of manic episodes (without psychotic features) of adolescents with bipolar mood disorder. The mood-stabilizing role of this drug might be mediated through its action on inflammatory cascades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Basselin, M., Kim, H.-W., Chen, M., Ma, K., Rapoport, S. I., Murphy, R. C., & Farias, S. E. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002469 · Cited by 52 · cited 2×
“Multiple investigations showed that IL-6 is suppressed in bi-polar patients under treatment with lithium and valproate (Breunis et al. 2003; Kim et al. 2007; Knijff et al. 2007; Basselin et al. 2010; Chiu et al. 2013).”
RetractedMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder
Brietzke, E., Stertz, L., Fernandes, B. S., Kauer-Sant’Anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J. A., & Kapczinski, F. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.12.001 · Cited by 423
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Self-citationImbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder
Kim, Y.-K., Jung, H.-G., Myint, A.-M., Kim, H., & Park, S.-H. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.018 · Cited by 375
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.
O'Brien, S. M., Scully, P., Scott, L. V., & Dinan, T. G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.11.015 · Cited by 285
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148 · cited 2×
“It was hypothesized that celecoxib might affect mood episodes by exerting its role as an anti-inflammatory drug (Nery et al. 2008; Guo et al. 2009; Stolk et al. 2010).”
Cytokine production in bipolar affective disorder patients under lithium treatment
Boufidou, F., Nikolaou, C., Alevizos, B., Liappas, I. A., & Christodoulou, G. N. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.01.007 · Cited by 130 · cited 1×
“Levels of these mediators seem to increase in manic and depressive phases of this disorder reaching a plateau in the euthymic phase, although some inconsistencies exist in the current literature regarding these reported changes (Breunis et al. 2003; Boufidou et al. 2004; Cunha et al. 2008; Brietzke et al. 2009).”
Mohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015592215 · Cited by 39
Self-citation
Cited by
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Revisiting inflammation in bipolar disorder
Fries, G. R., Walss-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.006 · Cited by 147
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Rapoport, S. I., & Hibbeln, J. R. (2020) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102118 · Cited by 11
Metadata
- Authors
- Mousavi, S. Y., Khezri, R., Karkhaneh-Yousefi, M.-A., Mohammadinejad, P., Gholamian, F., Mohammadi, M. R., Zeinoddini, A., & Akhondzadeh, S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2017-08
- Volume
- 27
- Issue
- 6
- Pages
- 494-500
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2612210401
- Cited by
- 61
- References
- 10
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.